Stem Cell Educator therapy
Throne Biotechnologies (formerly Tianhe Stem Cell Biotechnologies)
A dialysis-like procedure that circulates a person's blood through a device where their immune cells are briefly co-cultured with cord-blood-derived stem cells, then returned — aiming to 're-educate' the immune system rather than suppress it. Small early trials reported improved C-peptide, lower HbA1c and reduced insulin dose with a strong safety record, and the mechanism (immune re-balancing via cord-blood stem cells) is genuinely distinct. But controlled, adequately powered efficacy data are still lacking, and the registered phase 2/3 trial has been dormant on ClinicalTrials.gov for over two years with no results posted. It remains investigational.
The scorecard
An open-label phase 1/2 study reported improved basal and stimulated C-peptide and reduced insulin dose at up to 40 weeks, including in some long-standing patients — but it was small (n=15) and lacked a blinded, randomized comparator.[1]
Authors describe lasting metabolic improvement from a single treatment, but follow-up was limited and there is no large controlled trial confirming durable beta-cell preservation.[1]
The procedure was well tolerated with only minor venipuncture-related discomfort and no reported adverse events; importantly, the stem cells stay in the device and are not infused into the patient.[1]
Unusually broad for T1D immunotherapy — early studies treated both recent-onset and long-standing patients, including those with no residual C-peptide — but all evidence is from small single-arm cohorts.[1]
More than a decade of small international studies, but the pivotal picture has gone quiet: the registered phase 2/3 study (NCT04011020) now carries ClinicalTrials.gov's unknown-status flag — the sponsor has not verified it in over two years — its October 2024 primary completion date has passed, and no results have been posted. There is still no randomized efficacy trial and no regulatory approval.[3]
The full picture
Stem Cell Educator therapy takes an unusual angle on type 1 diabetes: instead of drugging or depleting the immune system, it tries to retrain it. In a single dialysis-like session lasting several hours, a person's blood is drawn and passed through a device where their immune cells are briefly co-cultured with multipotent stem cells derived from donated umbilical cord blood. The immune cells are then returned to the body, while the cord-blood stem cells stay behind in the device. The premise, developed by Yong Zhao and now advanced by Throne Biotechnologies, is that contact with these stem cells corrects underlying immune dysfunction — shifting cells toward regulatory, tolerance-promoting states through mechanisms the group attributes to factors such as the autoimmune regulator protein and galectin-9. Early open-label studies reported encouraging results: improved C-peptide, lower HbA1c, and reduced insulin requirements that persisted for months, even in some people with long-standing disease and little residual function. The safety record is a genuine strength, since nothing foreign is infused and side effects were minimal. The honest caveats are large, though. The supportive data come from small, mostly single-arm cohorts without the blinded, randomized, placebo-controlled design needed to prove a disease-modifying effect, and independent replication at scale is thin.
There is a newer concern too. The registered phase 2/3 trial (NCT04011020, 50 participants across two sites, sponsored by Throne Biotechnologies) has not been updated on ClinicalTrials.gov in over two years — it now carries the registry's "unknown status" flag, which means the study has passed its completion date without the sponsor verifying where it stands. Its planned primary completion date came and went in October 2024, and no results have been posted. Throne is still an operating company, so this is not evidence that the programme has been abandoned; but for a therapy whose whole case rests on getting rigorous controlled data, that silence is itself information, and we have marked the maturity score down for it.
It is a distinctive, mechanistically interesting platform that remains firmly investigational pending rigorous controlled trials.
Coming soon
ETA · Investigational, and the trail has gone cold: the registered phase 2/3 study has not been updated in over two years and has posted no results. Convincing controlled efficacy data are still needed.
Sources
- [1]Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells · peer-reviewed · 2012-01-10
- [2]Stem Cell Educator therapy in type 1 diabetes: From the bench to clinical trials · peer-reviewed · 2022-01-31
- [3]Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes · registry — Phase 2/3, sponsor Throne Biotechnologies, target enrolment 50 across 2 sites, started September 2022. Listed as unknown status on ClinicalTrials.gov as of July 2026 — the registry's flag for a study whose sponsor has not verified it in more than two years. The primary completion date of 20 October 2024 has passed with no results posted.